Jasper Historical Balance Sheet

JSPR Stock

USD 22.47 0.16 0.72%

Trend analysis of Jasper Therapeutics balance sheet accounts such as Total Current Liabilities of 7.4 M or Total Stockholder Equity of 82.4 M provides information on Jasper Therapeutics' total assets, liabilities, and equity, which is the actual value of Jasper Therapeutics to its prevalent stockholders. By breaking down trends over time using Jasper Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Jasper Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jasper Therapeutics is a good buy for the upcoming year.

Jasper Therapeutics Inventory

(468,540)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

About Jasper Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Jasper Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Jasper Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jasper Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jasper currently owns. An asset can also be divided into two categories, current and non-current.

Jasper Therapeutics Balance Sheet Chart

At this time, Jasper Therapeutics' Net Receivables is relatively stable compared to the past year. As of 12/11/2024, Common Stock Shares Outstanding is likely to grow to about 11 M, while Other Current Liabilities is likely to drop slightly above 3.7 M.

Other Current Liab Total Current Liabilities Other Liab Net Debt Other Assets

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Jasper Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Jasper Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Jasper Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.At this time, Jasper Therapeutics' Net Receivables is relatively stable compared to the past year. As of 12/11/2024, Common Stock Shares Outstanding is likely to grow to about 11 M, while Other Current Liabilities is likely to drop slightly above 3.7 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	3.1M	3.6M	6.3M	3.7M
Total Assets	93.7M	48.4M	94.9M	63.2M

Other Current Liab Total Assets

Jasper Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Warrants	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Total Current Assets	Non Current Liabilities Other
Total Assets		0.85	0.93	0.83	0.27	-0.79	-0.78	-0.96	-0.81	0.98	1.0	0.84	0.87	0.38	1.0	0.92	-0.83	-0.53	-0.02	0.92	0.79	0.87	0.29	0.7	1.0	0.52
Other Current Liab	0.85		0.98	0.64	-0.04	-0.94	-0.91	-0.8	-0.94	0.9	0.82	0.88	0.98	0.13	0.82	0.89	-0.88	-0.63	0.14	0.9	0.68	0.88	0.45	0.86	0.83	0.1
Total Current Liabilities	0.93	0.98		0.71	0.09	-0.94	-0.91	-0.87	-0.94	0.96	0.9	0.93	0.98	0.25	0.9	0.95	-0.92	-0.6	0.11	0.95	0.78	0.9	0.44	0.8	0.91	0.28
Total Stockholder Equity	0.83	0.64	0.71		-0.11	-0.63	-0.58	-0.9	-0.73	0.73	0.85	0.6	0.62	-0.05	0.85	0.74	-0.74	-0.68	-0.51	0.73	0.68	0.89	-0.18	0.69	0.84	0.28
Other Liab	0.27	-0.04	0.09	-0.11		0.09	-0.1	-0.17	0.14	0.33	0.27	0.21	0.08	0.98	0.27	0.14	0.03	0.33	0.6	0.14	0.2	-0.13	0.54	-0.33	0.28	0.85
Net Tangible Assets	-0.79	-0.94	-0.94	-0.63	0.09		0.88	0.72	0.94	-0.82	-0.74	-0.95	-0.97	-0.08	-0.74	-0.94	0.97	0.56	-0.07	-0.94	-0.84	-0.88	-0.39	-0.71	-0.76	-0.15
Warrants	-0.78	-0.91	-0.91	-0.58	-0.1	0.88		0.8	0.95	-0.87	-0.74	-0.91	-0.94	-0.29	-0.74	-0.81	0.89	0.75	-0.32	-0.82	-0.7	-0.87	-0.64	-0.76	-0.75	-0.17
Net Debt	-0.96	-0.8	-0.87	-0.9	-0.17	0.72	0.8		0.84	-0.93	-0.96	-0.76	-0.8	-0.28	-0.96	-0.83	0.8	0.72	0.1	-0.82	-0.7	-0.92	-0.23	-0.77	-0.96	-0.4
Retained Earnings	-0.81	-0.94	-0.94	-0.73	0.14	0.94	0.95	0.84		-0.85	-0.78	-0.89	-0.94	-0.04	-0.78	-0.86	0.94	0.81	-0.04	-0.87	-0.73	-0.96	-0.39	-0.86	-0.79	-0.05
Accounts Payable	0.98	0.9	0.96	0.73	0.33	-0.82	-0.87	-0.93	-0.85		0.96	0.89	0.92	0.46	0.96	0.91	-0.84	-0.55	0.17	0.91	0.76	0.85	0.48	0.71	0.97	0.49
Cash	1.0	0.82	0.9	0.85	0.27	-0.74	-0.74	-0.96	-0.78	0.96		0.79	0.82	0.37	1.0	0.88	-0.78	-0.53	-0.06	0.88	0.73	0.85	0.24	0.7	1.0	0.51
Non Current Assets Total	0.84	0.88	0.93	0.6	0.21	-0.95	-0.91	-0.76	-0.89	0.89	0.79		0.96	0.37	0.79	0.96	-0.96	-0.49	0.23	0.96	0.91	0.84	0.53	0.57	0.81	0.42
Non Currrent Assets Other	0.87	0.98	0.98	0.62	0.08	-0.97	-0.94	-0.8	-0.94	0.92	0.82	0.96		0.25	0.82	0.94	-0.94	-0.58	0.21	0.94	0.79	0.87	0.53	0.75	0.84	0.24
Other Assets	0.38	0.13	0.25	-0.05	0.98	-0.08	-0.29	-0.28	-0.04	0.46	0.37	0.37	0.25		0.37	0.27	-0.12	0.19	0.68	0.27	0.31	0.01	0.68	-0.19	0.37	0.82
Cash And Short Term Investments	1.0	0.82	0.9	0.85	0.27	-0.74	-0.74	-0.96	-0.78	0.96	1.0	0.79	0.82	0.37		0.88	-0.78	-0.53	-0.06	0.88	0.73	0.85	0.24	0.7	1.0	0.51
Common Stock Total Equity	0.92	0.89	0.95	0.74	0.14	-0.94	-0.81	-0.83	-0.86	0.91	0.88	0.96	0.94	0.27	0.88		-0.95	-0.45	0.0	1.0	0.92	0.87	0.32	0.62	0.9	0.45
Retained Earnings Total Equity	-0.83	-0.88	-0.92	-0.74	0.03	0.97	0.89	0.8	0.94	-0.84	-0.78	-0.96	-0.94	-0.12	-0.78	-0.95		0.62	0.02	-0.95	-0.91	-0.93	-0.33	-0.67	-0.8	-0.27
Short Term Investments	-0.53	-0.63	-0.6	-0.68	0.33	0.56	0.75	0.72	0.81	-0.55	-0.53	-0.49	-0.58	0.19	-0.53	-0.45	0.62		0.11	-0.45	-0.33	-0.81	-0.19	-0.85	-0.53	0.24
Non Current Liabilities Total	-0.02	0.14	0.11	-0.51	0.6	-0.07	-0.32	0.1	-0.04	0.17	-0.06	0.23	0.21	0.68	-0.06	0.0	0.02	0.11		0.01	-0.05	-0.18	0.93	-0.11	-0.05	0.18
Capital Surpluse	0.92	0.9	0.95	0.73	0.14	-0.94	-0.82	-0.82	-0.87	0.91	0.88	0.96	0.94	0.27	0.88	1.0	-0.95	-0.45	0.01		0.92	0.87	0.33	0.62	0.89	0.44
Other Current Assets	0.79	0.68	0.78	0.68	0.2	-0.84	-0.7	-0.7	-0.73	0.76	0.73	0.91	0.79	0.31	0.73	0.92	-0.91	-0.33	-0.05	0.92		0.78	0.23	0.35	0.76	0.58
Other Stockholder Equity	0.87	0.88	0.9	0.89	-0.13	-0.88	-0.87	-0.92	-0.96	0.85	0.85	0.84	0.87	0.01	0.85	0.87	-0.93	-0.81	-0.18	0.87	0.78		0.19	0.83	0.86	0.16
Total Liab	0.29	0.45	0.44	-0.18	0.54	-0.39	-0.64	-0.23	-0.39	0.48	0.24	0.53	0.53	0.68	0.24	0.32	-0.33	-0.19	0.93	0.33	0.23	0.19		0.2	0.26	0.23
Long Term Investments	0.7	0.86	0.8	0.69	-0.33	-0.71	-0.76	-0.77	-0.86	0.71	0.7	0.57	0.75	-0.19	0.7	0.62	-0.67	-0.85	-0.11	0.62	0.35	0.83	0.2		0.7	-0.24
Total Current Assets	1.0	0.83	0.91	0.84	0.28	-0.76	-0.75	-0.96	-0.79	0.97	1.0	0.81	0.84	0.37	1.0	0.9	-0.8	-0.53	-0.05	0.89	0.76	0.86	0.26	0.7		0.52
Non Current Liabilities Other	0.52	0.1	0.28	0.28	0.85	-0.15	-0.17	-0.4	-0.05	0.49	0.51	0.42	0.24	0.82	0.51	0.45	-0.27	0.24	0.18	0.44	0.58	0.16	0.23	-0.24	0.52

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Jasper Stock

0.68	IMAB	I Mab	Pair Corr
0.48	GNFT	Genfit	Pair Corr
0.45	LLY	Eli Lilly	Pair Corr
0.44	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.4	FLGC	Flora Growth Corp	Pair Corr

The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.

The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jasper Historical Balance Sheet

Jasper Therapeutics Inventory

(468,540)

About Jasper Balance Sheet Analysis

Jasper Therapeutics Balance Sheet Chart

Total Current Liabilities

Net Debt

Jasper Therapeutics balance sheet Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Jasper Therapeutics

Moving against Jasper Stock

Additional Tools for Jasper Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Non Currrent Assets Other	- 0.97	Net Tangible Assets
Retained Earnings Total Equity	- 0.96	Non Current Assets Total
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt